SCIENTIFIC HIGHLIGHTS

CCL21-loaded 3D hydrogels for T cell expansion and differentiation
09 October 2020

Eduardo Pérez del Río, Fabião Santos, Xavier Rodriguez Rodriguez, Marc Martínez-Miguel, Ramon Roca-Pinilla, Anna Arís, Elena Garcia-Fruitós, Jaume Veciana, Joachim P. Spatz, Imma Ratera, Judith Guasch. Biomaterials Volume 259, November 2020, 120313. 

DOI: 10.1016/j.biomaterials.2020.120313

Recent achievements in the field of immunotherapy, such as the development of engineered T cells used in adoptive cell therapy, are introducing more efficient strategies to combat cancer. Nevertheless, there are still many limitations. For example, these T cells are challenging to manufacture, manipulate, and control. Specifically, there are limitations in producing the large amounts of therapeutic T cells needed for these therapies in a short period of time and in an economically viable manner. In this study, three-dimensional (3D) poly(ethylene) glycol (PEG) hydrogels covalently combined with low molecular weight heparin are engineered to resemble the lymph nodes, where T cells reproduce.

In these hydrogels, PEG provides the needed structural and mechanical properties, whereas heparin is used as an anchor for the cytokine CCL21, which is present in the lymph nodes, and can affect cell migration and proliferation. The 3D structure of the hydrogel in combination with its loading capacity result in an increased primary human CD4+ T cell proliferation compared to the state-of-the-art expansion systems consisting of artificial antigen presenting cells. Thus, we present a new tool for adoptive cell therapy to help achieving the large numbers of cells required for therapy of selected phenotypes targeted against cancer cells, by mimicking the lymph nodes.

CCL21-loaded 3D hydrogels for T cell expansion and differentiation

 
Hits: 485
Bioactive materials for therapy and diagnosis

CCL21-loaded 3D hydrogels for T cell expansion and differentiation



Also at ICMAB


INSTITUT DE CIÈNCIA DE MATERIALS DE BARCELONA, Copyright © 2020 ICMAB-CSIC | Privacy Policy | This email address is being protected from spambots. You need JavaScript enabled to view it.